Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Keros Therapeutics ( (KROS) ).
On March 4, 2026, Keros Therapeutics updated its corporate presentation for use in meetings with investors, analysts and other stakeholders, making it available on its website. The presentation outlines the company’s strategy to leverage TGF-β pathway modulation across a broad portfolio, including neuromuscular, myelodysplastic, myelofibrosis, obesity and frailty indications, reinforcing its positioning as a platform-based rare disease and specialty therapeutics player.
A central focus of the updated materials is rinvatercept (KER-065), an investigational modified activin receptor type II ligand trap designed to inhibit specific TGF-β ligands such as activin A and myostatin. The company highlights preclinical data suggesting rinvatercept may improve muscle regeneration, reduce inflammation and fibrosis, lower fat accumulation and support bone health, particularly in Duchenne muscular dystrophy and other neuromuscular diseases where current treatments leave significant unmet need.
The deck emphasizes that neuromuscular disorders like Duchenne muscular dystrophy, Becker muscular dystrophy, limb-girdle muscular dystrophy, congenital muscular dystrophy and amyotrophic lateral sclerosis share downstream skeletal muscle pathology that rinvatercept could potentially address. By framing rinvatercept as a systemic, disease-modifying approach that might complement gene therapy, exon-skipping and glucocorticoids, Keros underscores its ambition to capture a meaningful role in the evolving care paradigm for rare neuromuscular conditions.
The most recent analyst rating on (KROS) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
The score is driven primarily by improving financial performance and a strong, low-leverage balance sheet, supported by reasonable valuation and positive corporate actions (capital return and strategy updates). These positives are tempered by weaker near-term technical momentum (negative MACD, RSI below 50, and price below the 20-day average).
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing differentiated product candidates that modulate transforming growth factor-beta (TGF-β) signaling. Its pipeline includes rinvatercept (KER-065) and elritercept (KER-050), targeting neuromuscular, hematologic and rare bone or fibrotic disorders with high unmet medical need.
Average Trading Volume: 415,343
Technical Sentiment Signal: Sell
Current Market Cap: $408.2M
See more insights into KROS stock on TipRanks’ Stock Analysis page.